What is Dimerix Limited's official website?

Dimerix Limited's website is dimerix.com

How many employees are working in Dimerix Limited right now?

Dimerix Limited has 18 employees.

What is Dimerix Limited's industry?

Dimerix Limited's industry is Pharmaceutical Manufacturing

Who are Dimerix Limited's top competitors?

Dimerix Limited's top competitors are , , , , , ,

Dimerix Limited company information, Employees & Contact Information

Explore related pages

Dimerix Limited email format Dimerix Limited management contacts

Related company profiles:

Dimerix (ASX:DXB) is a clinical-stage biopharmaceutical company with a portfolio of drug candidates for inflammatory diseases, including kidney and respiratory diseases. Dimerix’ lead clinical asset, DMX-200 (or QYTOVRA® in some territories), is in Phase 3 trials as a treatment for focal segmental glomerulosclerosis (FSGS), a rare kidney disease.

Employees: 18
Address: Melbourne, Victoria 3000, Au
Phone: 61409050519
Email: in****@****rix.com
Industry: Pharmaceutical Manufacturing
NAICS: Pharmaceutical and Medicine Manufacturing

Medicinal and Botanical Manufacturing

Pharmaceutical Preparation Manufacturing

In-Vitro Diagnostic Substance Manufacturing

Biological Product (except Diagnostic) Manufacturing
Website: dimerix.com
Keywords: Biotechnology, Drug Development, Chronic Kidney Disease, Nephrology, In Vitro Screening, Platform technology, Clinical Research, Drug Discovery, Diabetic Kidney Disease.
HQ: Melbourne, Victoria
Competitors: Kinoxis Therapeutics Pty Ltd, Euroz Hartleys Limited, Kira Biotech Pty Ltd, Argenica Therapeutics, Syntara, Amicus Therapeutics, IDT Australia Limited, Paradigm Biopharmaceuticals, Orthocell Ltd, Neuren Pharmaceuticals Limited.

Dimerix Limited Questions

News

Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States - Yahoo Finance

Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States Yahoo Finance

FDA confirms primary goal for Dimerix’s DMX-200 trial to treat FSGS - Clinical Trials Arena

FDA confirms primary goal for Dimerix’s DMX-200 trial to treat FSGS Clinical Trials Arena

Final data analysis by the PARASOL collaboration with Dimerix - The Pharma Letter

Final data analysis by the PARASOL collaboration with Dimerix The Pharma Letter

Amicus pays Dimerix $30M for late-phase rare kidney disease drug - Fierce Biotech

Amicus pays Dimerix $30M for late-phase rare kidney disease drug Fierce Biotech

Dimerix reports positive outcome from PARASOL collaboration - BiotechDispatch

Dimerix reports positive outcome from PARASOL collaboration BiotechDispatch

ASX Penny Stocks Spotlight Dimerix And Two More Hidden Gems - Yahoo Finance

ASX Penny Stocks Spotlight Dimerix And Two More Hidden Gems Yahoo Finance

Dimerix gets first milestone from FUSO Pharma - The Pharma Letter

Dimerix gets first milestone from FUSO Pharma The Pharma Letter

Long Shortz: Dimerix - The Australian

Long Shortz: Dimerix The Australian

Biocurious: Dimerix could be riding big and beautiful kidney drug success earlier than expected - Stockhead

Biocurious: Dimerix could be riding big and beautiful kidney drug success earlier than expected Stockhead

Dimerix and Amicus to commercialise DMX-200 in US - Pharmaceutical Technology

Dimerix and Amicus to commercialise DMX-200 in US Pharmaceutical Technology

Hot Stocks: Block, Ainsworth Game Technology, Mineral Resources, Dimerix - Finance News Network

Hot Stocks: Block, Ainsworth Game Technology, Mineral Resources, Dimerix Finance News Network

Long Shortz: Dimerix - The Australian

Long Shortz: Dimerix The Australian

Health Check: Dimerix shares soar as the company hooks the billion-dollar big one in the US - Stockhead

Health Check: Dimerix shares soar as the company hooks the billion-dollar big one in the US Stockhead

Dr Boreham’s Crucible: The wheels keep turning for Dimerix and its kidney drug candidate - Stockhead

Dr Boreham’s Crucible: The wheels keep turning for Dimerix and its kidney drug candidate Stockhead

Dimerix secures exclusive US licence agreement with Amicus Therapeutics - BiotechDispatch

Dimerix secures exclusive US licence agreement with Amicus Therapeutics BiotechDispatch

Dimerix chief to join Imagion board - The Australian

Dimerix chief to join Imagion board The Australian

Dimerix sells rights to Amicus for DMX-200 in USA - The Pharma Letter

Dimerix sells rights to Amicus for DMX-200 in USA The Pharma Letter

Dimerix hits 70pc recruitment milestone in rare kidney disease drug trial - Stockhead

Dimerix hits 70pc recruitment milestone in rare kidney disease drug trial Stockhead

Dimerix enters deal with FUSO for DMX-200 Japan - The Pharma Letter

Dimerix enters deal with FUSO for DMX-200 Japan The Pharma Letter

ASX Health Quarterly Wrap: Dimerix inks fourth licensing deal, Audeara nails record revenue year - Stockhead

ASX Health Quarterly Wrap: Dimerix inks fourth licensing deal, Audeara nails record revenue year Stockhead

Dimerix (ASX:DXB): This exciting Phase 3 biotech could be about to follow in the footsteps of Telix and Neuren - Stocks Down Under

Dimerix (ASX:DXB): This exciting Phase 3 biotech could be about to follow in the footsteps of Telix and Neuren Stocks Down Under

Dimerix says the recruitment of adolescent patients to commence in Phase 3 trial - BiotechDispatch

Dimerix says the recruitment of adolescent patients to commence in Phase 3 trial BiotechDispatch

We're Interested To See How Dimerix (ASX:DXB) Uses Its Cash Hoard To Grow - simplywall.st

We're Interested To See How Dimerix (ASX:DXB) Uses Its Cash Hoard To Grow simplywall.st

Dimerix announces successful collection of data for first patients in ACTION3 trial - BiotechDispatch

Dimerix announces successful collection of data for first patients in ACTION3 trial BiotechDispatch

Dimerix raises $20 million to continue and expand late-stage clinical trial of DMX-200 - BiotechDispatch

Dimerix raises $20 million to continue and expand late-stage clinical trial of DMX-200 BiotechDispatch

PARASOL data boost for Dimerix - The Australian

PARASOL data boost for Dimerix The Australian

Dimerix’s DMX-200 Gains Orphan Drug Status in Japan - MSN

Dimerix’s DMX-200 Gains Orphan Drug Status in Japan MSN

Recruitment on track for Dimerix’s global kidney disease trial - Stockhead

Recruitment on track for Dimerix’s global kidney disease trial Stockhead

Vital Signs Podcast: Dimerix - The Australian

Vital Signs Podcast: Dimerix The Australian

Dimerix announces Middle East license agreement for DMX-200 - BiotechDispatch

Dimerix announces Middle East license agreement for DMX-200 BiotechDispatch

Dimerix opens first Japan kidney trial site - The Australian

Dimerix opens first Japan kidney trial site The Australian

Dimerix banks $3.2m from Japanese deal - The Australian

Dimerix banks $3.2m from Japanese deal The Australian

Key findings could boost Dimerix’s rare kidney disease drug trial - Stockhead

Key findings could boost Dimerix’s rare kidney disease drug trial Stockhead

Interim results for Dimerix’s Phase 3 trial of DXB-200 for FSGS kidney disease on track for release in March 2024 - Stockhead

Interim results for Dimerix’s Phase 3 trial of DXB-200 for FSGS kidney disease on track for release in March 2024 Stockhead

Dimerix secures Japan deal for kidney drug - The Australian

Dimerix secures Japan deal for kidney drug The Australian

Bio Curious: How Dimerix negotiates the 'valleys of death' on the winding road to drug approval - Stockhead

Bio Curious: How Dimerix negotiates the 'valleys of death' on the winding road to drug approval Stockhead

Dimerix announces new patent family for DMX-700 - BiotechDispatch

Dimerix announces new patent family for DMX-700 BiotechDispatch

Dimerix enters agreement for new trial of DMX-200 in diabetic kidney disease - BiotechDispatch

Dimerix enters agreement for new trial of DMX-200 in diabetic kidney disease BiotechDispatch

Dimerix completes ‘highly strategic’ $20m cap raise to advance ACTION3 Phase 3 trial - Stockhead

Dimerix completes ‘highly strategic’ $20m cap raise to advance ACTION3 Phase 3 trial Stockhead

Dimerix updates with new and positive DMX-700 data - BiotechDispatch

Dimerix updates with new and positive DMX-700 data BiotechDispatch

Dr Boreham’s Crucible: Dimerix has so far proved the doubters wrong. Next stop – the US - Stockhead

Dr Boreham’s Crucible: Dimerix has so far proved the doubters wrong. Next stop – the US Stockhead

ASX 200 Penny Stocks Watchlist: Aussie Broadband and Dimerix in Focus - Kalkine Media

ASX 200 Penny Stocks Watchlist: Aussie Broadband and Dimerix in Focus Kalkine Media

Dimerix reports positive results from DMX-200 trial - BiotechDispatch

Dimerix reports positive results from DMX-200 trial BiotechDispatch

Dimerix (ASX:DXB) - Stockhead

Dimerix (ASX:DXB) Stockhead

Synertec Corporation, Dimerix mop up equity raisings - AFR

Synertec Corporation, Dimerix mop up equity raisings AFR

Dimerix HIT Assay to Understand Receptor Interactions Applied to Kinase Targets - Technology Networks

Dimerix HIT Assay to Understand Receptor Interactions Applied to Kinase Targets Technology Networks

Companies like Dimerix Limited

Top Dimerix Limited Employees

Mark Diamond

n/a

Melbourne, Victoria, Australia, Australia

View

2
hotmail.com, antisense.com.au
Robert Shepherd

Chief Commercialisation Officer (Cco)…

N/a

View
Sonia Poli

Senior Executive Leader, Pharma R&D…

N/a

View
Kevin Pfleger

Director, Biomedical And Health…

N/a

View

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles

Get direct phone numbers & mobile contacts

Access company data & employee information

Works directly on LinkedIn - no copy/paste needed

Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant

Learn More

How It Works

Get a Free Account

Search the #1 Contact Database

Get contact details of over 750M+ profiles across 60M companies – all with industry-leading accuracy. Sales Navigator and Recruiter users, try out our Email Finder Extension.

Use our AI-Powered Email Finder

Find business and personal emails and mobile phone numbers with exclusive coverage across niche job titles, industries, and more for unparalleled targeting. Also available via our Contact Data API.

Have a look at Aeroleads Data

Browse our Data

Company Search

a b c d e f g h i j k l m n o p q r s t u v w x y z

Profile Search

a b c d e f g h i j k l m n o p q r s t u v w x y z

List Search

a b c d e f g h i j k l m n o p q r s t u v w x y z

Dimerix Limited company information, Employees & Contact Information

Explore related pages

Company Details

Dimerix Limited Questions

What is Dimerix Limited's helpline number?

What is Dimerix Limited's official website?

What is Dimerix Limited's LinkedIn profile?

How many employees are working in Dimerix Limited right now?

What is Dimerix Limited's industry?

What are Dimerix Limited's top competitors?

What is Dimerix Limited's support email address?

What are Dimerix Limited's categories?

News

Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States - Yahoo Finance

FDA confirms primary goal for Dimerix’s DMX-200 trial to treat FSGS - Clinical Trials Arena

Final data analysis by the PARASOL collaboration with Dimerix - The Pharma Letter

Amicus pays Dimerix $30M for late-phase rare kidney disease drug - Fierce Biotech

Dimerix reports positive outcome from PARASOL collaboration - BiotechDispatch

ASX Penny Stocks Spotlight Dimerix And Two More Hidden Gems - Yahoo Finance

Dimerix gets first milestone from FUSO Pharma - The Pharma Letter

Long Shortz: Dimerix - The Australian

Biocurious: Dimerix could be riding big and beautiful kidney drug success earlier than expected - Stockhead

Dimerix and Amicus to commercialise DMX-200 in US - Pharmaceutical Technology

Hot Stocks: Block, Ainsworth Game Technology, Mineral Resources, Dimerix - Finance News Network

Long Shortz: Dimerix - The Australian

Health Check: Dimerix shares soar as the company hooks the billion-dollar big one in the US - Stockhead

Dr Boreham’s Crucible: The wheels keep turning for Dimerix and its kidney drug candidate - Stockhead

Dimerix secures exclusive US licence agreement with Amicus Therapeutics - BiotechDispatch

Dimerix chief to join Imagion board - The Australian

Dimerix sells rights to Amicus for DMX-200 in USA - The Pharma Letter

Dimerix hits 70pc recruitment milestone in rare kidney disease drug trial - Stockhead

Dimerix enters deal with FUSO for DMX-200 Japan - The Pharma Letter

ASX Health Quarterly Wrap: Dimerix inks fourth licensing deal, Audeara nails record revenue year - Stockhead

Dimerix (ASX:DXB): This exciting Phase 3 biotech could be about to follow in the footsteps of Telix and Neuren - Stocks Down Under

Dimerix says the recruitment of adolescent patients to commence in Phase 3 trial - BiotechDispatch

We're Interested To See How Dimerix (ASX:DXB) Uses Its Cash Hoard To Grow - simplywall.st

Dimerix announces successful collection of data for first patients in ACTION3 trial - BiotechDispatch

Dimerix raises $20 million to continue and expand late-stage clinical trial of DMX-200 - BiotechDispatch

PARASOL data boost for Dimerix - The Australian

Dimerix’s DMX-200 Gains Orphan Drug Status in Japan - MSN

Recruitment on track for Dimerix’s global kidney disease trial - Stockhead

Vital Signs Podcast: Dimerix - The Australian

Dimerix announces Middle East license agreement for DMX-200 - BiotechDispatch

Dimerix opens first Japan kidney trial site - The Australian

Dimerix banks $3.2m from Japanese deal - The Australian

Key findings could boost Dimerix’s rare kidney disease drug trial - Stockhead

Interim results for Dimerix’s Phase 3 trial of DXB-200 for FSGS kidney disease on track for release in March 2024 - Stockhead

Dimerix secures Japan deal for kidney drug - The Australian

Bio Curious: How Dimerix negotiates the 'valleys of death' on the winding road to drug approval - Stockhead

Dimerix announces new patent family for DMX-700 - BiotechDispatch

Dimerix enters agreement for new trial of DMX-200 in diabetic kidney disease - BiotechDispatch

Dimerix completes ‘highly strategic’ $20m cap raise to advance ACTION3 Phase 3 trial - Stockhead

Dimerix updates with new and positive DMX-700 data - BiotechDispatch

Dr Boreham’s Crucible: Dimerix has so far proved the doubters wrong. Next stop – the US - Stockhead

ASX 200 Penny Stocks Watchlist: Aussie Broadband and Dimerix in Focus - Kalkine Media

Dimerix reports positive results from DMX-200 trial - BiotechDispatch

Dimerix (ASX:DXB) - Stockhead

Synertec Corporation, Dimerix mop up equity raisings - AFR

Dimerix HIT Assay to Understand Receptor Interactions Applied to Kinase Targets - Technology Networks

Companies like Dimerix Limited

Paradigm Biopharmace...

Kinoxis Therapeutics...

Orthocell Ltd

Neuren Pharmaceutica...

Euroz Hartleys Limited

Kira Biotech Pty Ltd

Argenica Therapeutics

Syntara

Amicus Therapeutics

Idt Australia Limited

Top Dimerix Limited Employees

Mark Diamond

n/a

Robert Shepherd

Chief Commercialisation Officer (Cco)…

Sonia Poli

Senior Executive Leader, Pharma R&D…

Kevin Pfleger

Director, Biomedical And Health…

Free Chrome Extension